drugset / Trial / NCT07579208
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find the best method of administering NK cells in patients with recurrent glioblastoma.
Timeline
- Start
- 2026-10-24
- Primary completion
- 2028-07-30
- Completion
- 2030-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | Other |